Clinical Trial Update: Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ferric carboxymaltose for iron deficiency anemia in patients with impaired renal function has completed and results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Renal Function
• Iron Deficiency Anemia

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Iron Deficiency Anemia, Impaired Renal Function | Phase 3 | Status: COMPLETED | Results posted: 2013-10-18